Stocksigma LogoStocksigma Logo

NATCO Pharma Reports Q2 FY27 Consolidated Financial and Operational Results

NATCO Pharma reported Q2 FY27 consolidated revenue of INR 10,194 Mn, down YoY from INR 14,630 Mn in Q2 FY26 but up QoQ from INR 7,944 Mn in Q1 FY27

NATCO Pharma Reports Q2 FY27 Consolidated Financial and Operational Results

Natco Pharma Ltd 路 Investor Presentation 路 13 Nov 2026, 9:27 pm

NATCO Pharma Reports Q2 FY27 Consolidated Financial and Operational Results NATCO Pharma reported Q2 FY27 consolidated revenue of INR 10,194 Mn, down YoY from INR 14,630 Mn in Q2 FY26 but up QoQ from INR 7,944 Mn in Q1 FY27. EBITDA stood at INR 3,100 Mn with a 30.4% margin. Net profit reached INR 2,026 Mn, delivering an EPS of INR 11.31. International formulations contributed INR 6,684 Mn, while domestic formulations generated INR 1,457 Mn. The company raised its stake in Adcock Ingram to 49% and expanded its US pipeline to 29 Para IV filings, including 20+ FTFs.

Original exchange filing (PDF)

More announcements from Natco Pharma Ltd

All Natco Pharma Ltd announcements